These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30116528)

  • 1. Atezolizumab-related encephalitis in the intensive care unit: Case report and review of the literature.
    Laserna A; Tummala S; Patel N; El Hamouda DEM; Gutiérrez C
    SAGE Open Med Case Rep; 2018; 6():2050313X18792422. PubMed ID: 30116528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report.
    Yamaguchi Y; Nagasawa H; Katagiri Y; Wada M
    J Med Case Rep; 2020 Jul; 14(1):88. PubMed ID: 32620173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: a case report and review of neurological adverse events associated with checkpoint inhibitors.
    Nader R; Tannoury E; Rizk T; Ghanem H
    Autops Case Rep; 2021 Apr; 11():e2021261. PubMed ID: 33968830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab-induced encephalitis with subdural hemorrhage and subarachnoid hemorrhage in a patient with hepatocellular carcinoma.
    Chao KH; Tseng TC
    J Formos Med Assoc; 2023 Nov; 122(11):1208-1212. PubMed ID: 37567840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hope, Cure, and Adverse Effects in Immunotherapy: Atezolizumab-Associated Encephalitis in Metastatic Small Cell Lung Cancer - A Case Report and Literature Review.
    Ibrahim EY; Zhao WC; Mopuru H; Janowiecki C; Regelmann DJ
    Case Rep Neurol; 2022; 14(3):366-371. PubMed ID: 36824581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab-associated encephalitis in metastatic breast cancer: A case report.
    Chen G; Zhang C; Lan J; Lou Z; Zhang H; Zhao Y
    Oncol Lett; 2022 Sep; 24(3):324. PubMed ID: 35949609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab-induced Autoimmune Diabetes in a Patient with Metastatic Breast Cancer: A Case Report.
    Clontz R; Dang DM; Hieger MA; Becker BA
    Clin Pract Cases Emerg Med; 2021 May; 5(2):190-193. PubMed ID: 34437002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit.
    Joseph A; Simonaggio A; Stoclin A; Vieillard-Baron A; Geri G; Oudard S; Michot JM; Lambotte O; Azoulay E; Lemiale V
    Ann Intensive Care; 2020 Oct; 10(1):143. PubMed ID: 33064239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smallpox vaccination and adverse reactions. Guidance for clinicians.
    Cono J; Casey CG; Bell DM;
    MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
    Lemiale V; Meert AP; Vincent F; Darmon M; Bauer PR; Van de Louw A; Azoulay E;
    Ann Intensive Care; 2019 Feb; 9(1):25. PubMed ID: 30707321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab-related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report.
    Jingu D; Horii A; Yajima T; Ohira R; Ubukata S; Satou K; Takahashi H; Watanabe H; Funayama H
    Respirol Case Rep; 2024 Mar; 12(3):e01324. PubMed ID: 38481422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC.
    Toyozawa R; Haratake N; Toyokawa G; Matsubara T; Takamori S; Miura N; Yamaguchi M; Takenoyama M; Seto T
    JTO Clin Res Rep; 2020 Mar; 1(1):100012. PubMed ID: 34589914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report.
    Kopecký J; Kubeček O; Geryk T; Slováčková B; Hoffmann P; Žiaran M; Priester P
    J Med Case Rep; 2018 Sep; 12(1):262. PubMed ID: 30217214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 18. De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma.
    Thakolwiboon S; Karukote A; Wilms H
    Cureus; 2019 Jun; 11(6):e5002. PubMed ID: 31497433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin autoimmunity might be associated with increased efficacy of atezolizumab in metastatic urothelial carcinoma: a case report.
    Rkman D; Likić R; Bebek M; Gnjidić M; Gamulin M
    Croat Med J; 2019 Dec; 60(6):552-555. PubMed ID: 31894921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
    McDermott DF; Sosman JA; Sznol M; Massard C; Gordon MS; Hamid O; Powderly JD; Infante JR; Fassò M; Wang YV; Zou W; Hegde PS; Fine GD; Powles T
    J Clin Oncol; 2016 Mar; 34(8):833-42. PubMed ID: 26755520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.